ELUXA 1: Phase II trial of olmutinib in patients with EGFR T790M mutation-positive lung cancer, following initial EGFR TKI treatment

ELUXA 2: Phase III trial of olmutinib versus standard platinum-doublet chemotherapy for patients with EGFR T790M mutation-positive lung cancer, whose disease progressed on one prior EGFR TKI treatment

ELUXA 3: Phase III head-to-head trial of olmutinib as a first-line treatment compared to Gilotrif in patients with EGFR mutation-positive NSCLC

ELUXA 4: Phase I/II trial in Japanese patients with EGFR T790M mutation-positive NSCLC

ELUXA 6: Phase II study with blood-based biomarker testing to select patients with EGFR T790M mutation-positive NSCLC where a needle biopsy may not be appropriate

*Trials announced to date, program will also include combination studies

Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base

More from Anticancer

More from Therapeutic Category